Literature DB >> 9447596

Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells.

V Patzel1, G Sczakiel.   

Abstract

The success of antisense therapeutics is not predictable despite their widespread use in biotechnology and molecular medicine. The relationship between RNA structure and biological effectiveness is largely not understood; however, antisense RNA-mediated effects in vivo seem to be related to annealing kinetics in vitro. This study suggests that terminal unpaired nucleotides and overall flexibility of antisense RNA directed against the human immunodeficiency virus type 1 (HIV-1) are related to fast RNA-RNA annealing in vitro as well as to strong inhibition of virus replication in human cells. Annealing rate constants of computer-selected antisense RNA species approach the values for natural antisense RNA in the order of 10(6) M-1s-1. When considering the unfavorable stability in cellular extracts of antisense RNA species that were found to anneal fast in vitro, an antisense effect against HIV-1 in human cells was observed that was 10- to 10,000-fold stronger than that measured for species predicted to anneal slowly. A computer-supported structural design of antisense RNA can serve as a platform to determine RNA-RNA association in vitro and biological effectiveness in living cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9447596     DOI: 10.1038/nbt0198-64

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  27 in total

1.  Toward antiviral strategies that resist viral escape.

Authors:  D Endy; J Yin
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Modeling RNA folding paths with pseudoknots: application to hepatitis delta virus ribozyme.

Authors:  H Isambert; E D Siggia
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells.

Authors:  G M Arndt; M Patrikakis; D Atkins
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

4.  Progression of a loop-loop complex to a four-way junction is crucial for the activity of a regulatory antisense RNA.

Authors:  F A Kolb; H M Engdahl; J G Slagter-Jäger; B Ehresmann; C Ehresmann; E Westhof; E G Wagner; P Romby
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

5.  RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA.

Authors:  M Warashina; T Kuwabara; Y Kato; M Sano; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

6.  Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo.

Authors:  M Sohail; H Hochegger; A Klotzbücher; R L Guellec; T Hunt; E M Southern
Journal:  Nucleic Acids Res       Date:  2001-05-15       Impact factor: 16.971

Review 7.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

8.  Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling.

Authors:  L Torner; N Toschi; A Pohlinger; R Landgraf; I D Neumann
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

9.  The impact of mRNA structure on guide RNA targeting in kinetoplastid RNA editing.

Authors:  Larissa Reifur; Laura E Yu; Jorge Cruz-Reyes; Michelle Vanhartesvelt; Donna J Koslowsky
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

10.  A genomic selection strategy to identify accessible and dimerization blocking targets in the 5'-UTR of HIV-1 RNA.

Authors:  Martin R Jakobsen; Christian K Damgaard; Ebbe S Andersen; Anna Podhajska; Jørgen Kjems
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.